Abstract 180P
Background
Intrahepatic cholangiocarcinoma(iCCA) is the second most common primary hepatic malignancy after hepatocellular carcinoma (HCC), and is also a highly malignant type of tumor. It is necessary to identify novel therapeutic targets.Histidine phosphatase LHPP were reported as a tumor suppressor for Hepatocellular Carcinoma and cervical cancer. And low level LHPP enhanced cell progression and tumor formation, and was associated with poor prognosis. So, we hypothesized that LHPP might be also related to the tumorigenesis of iCCA.
Methods
We analyzed the expression and clinical significance of LHPP in TCGA cohort and patient tissues. We transfected the iCCA cell lines with LHPP over-expression lentivirus or small interfering RNA. Cell proliferation were evaluated with the CCK-8 and colony formation assays. Cell apoptosis was evaluated by Annexin V/PI staining.Transwell assays were performed to assess cell invasion. Gene Set Enrichment Analysis (GSEA) was performed to enrich genes associated with LHPP. Markers of EMT and TGFβ/SMAD3 signaling pathway were evaluated by real-time PCR and western blotting.
Results
In this study, we found the mRNA and protein level of LHPP were downregulated in tumor tissues, and low level LHPP predicted a poor survival. LHPP overexpression suppressed RBE and HCCC-9810 cells growth and colony formation, and moderately promote cell apoptosis and EMT. In contrast, accumulated cell growth, colony formation, cell invasion and EMT were observed in LHPP knock down cells. We divided samples from the TCGA-CHOL cohort into two sub-group (LHPP_low and LHPP_High) by medina expression of LHPP, and found that TGFβ signaling pathway was significantly activated in LHPP_low group. The expression of TGFβ1 was negatively correlated with LHPP. We found that the expression of TGFβ1, TGFβ1R and p-SMAD3 were downregulated in LHPP overexpression cells, and these proteins were upregulated in LHPP down-expression cells.
Conclusions
We demonstrated that LHPP also serve as a suppressor gene to inhibit cell proliferation, cell invasion and EMT. And low level LHPP which was observed in tumor tissues predicted a poor survival. Mechanically, low level LHPP activate TGFβ/SMAD3 signaling pathway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract